Health and Healthcare
Gilead Paying Up (too much) for Pharmasset (GILD, VRUS)
Published:
Last Updated:
Gilead Sciences Inc. (NASDAQ: GILD) is trading lower on news that it is spending some $11 billion to buy Pharmasset, Inc. (NASDAQ: VRUS). What is interesting is that Pharmasset was valued only at $5.5 billion on Friday and shares were already close all-time highs. The $72.67 close compared to a 52-week and all-time high of $88.52 and the consensus analyst price target from Thomson Reuters was $99.69.
Gilead is placing a huge bet on its hepatitis C treatments at $137.00 per share. The deal is also an all-cash deal. Pharmasset has recently moved into late-stage hepatitis C drug and it currently plans on two additional late-stage trials in 2012.
Pharmasset was an attractive company, but this one seems like Gilead is spending above and beyond a normal amount here to close this deal. While less was known 12 or 18 months ago, Gilead would have been in close enough of the same position to have done a deal then at a far lower price. Still, that would have required knowing its drugs were going to live up to expectations.
Analysts expect virtually no revenues from Pharmasset for the next 24 months and Gilead has a market cap of $29.9 billion.
JON C. OGG
Is Your Money Earning the Best Possible Rate? (Sponsor)
Let’s face it: If your money is just sitting in a checking account, you’re losing value every single day. With most checking accounts offering little to no interest, the cash you worked so hard to save is gradually being eroded by inflation.
However, by moving that money into a high-yield savings account, you can put your cash to work, growing steadily with little to no effort on your part. In just a few clicks, you can set up a high-yield savings account and start earning interest immediately.
There are plenty of reputable banks and online platforms that offer competitive rates, and many of them come with zero fees and no minimum balance requirements. Click here to see if you’re earning the best possible rate on your money!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
